Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06912087 · ClinicalTrials.gov registry record · Phase 1

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

A Phase 1 study of Neoplasm Metastasis and Head and Neck Neoplasms, sponsored by University of Chicago.

Recruiting
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT06912087 is a Phase 1 study of Neoplasm Metastasis and Head and Neck Neoplasms that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 36 participants, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06912087, a Phase 1 study of Neoplasm Metastasis and Head and Neck Neoplasms, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The study aims to establish the maximally tolerated dose (MTD) and recommended Phase II dose (RP2D) while also exploring efficacy outcomes, including progression-free survival (PFS) and overall survival (OS).

Conditions Studied

Neoplasm Metastasis Head and Neck Neoplasms Carcinoma, Squamous Cell Metastatic Squamous Cell Carcinoma Recurrent Squamous Cell Carcinoma Neoplasm Recurrence, Local

Interventions

  • DRUG Pembrolizumab
  • DRUG Zanzalintinib
  • DRUG Cetuximab

Study Locations (1)

Illinois

  • University of Chicago Medicine Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2025-09-29
Est. Completion 2027-06-05
Phase Phase 1

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06912087

The ClinicalTrials.gov registry entry for NCT06912087 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (91% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT06912087 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06912087 about?

NCT06912087 is a clinical study titled "Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC". This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The study aims to establish the maximally tolerat...

What is the current status of trial NCT06912087?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-09-29. Estimated completion is 2027-06-05.

What conditions does trial NCT06912087 study?

This clinical trial studies the following conditions: Neoplasm Metastasis, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma.

What interventions are being tested in trial NCT06912087?

The interventions under investigation include: Pembrolizumab (DRUG), Zanzalintinib (DRUG), Cetuximab (DRUG).

Who is sponsoring clinical trial NCT06912087?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06912087 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm Metastasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasm Metastasis

All registered trials for this condition

Head and Neck Neoplasms

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.